EPHA2 and sarcoma: While tyrosine kinase inhibitors blocking EphA2 or VEGF-C signaling are already being tested as potential targets for sarcomas [19], [20], no information about the biological role of ErbB3 in pediatric rhabdomyosarcoma is currently available.